Latest papers

[Change of concentration endothelin-1 in rats on a background of alcohol and /or mildronate treatment]

Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics.

Uptake of cardiovascular drugs into the human heart: expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5).

[Effects of metabolic triad (25% polarizing solution, mildronat, preductal MR) in acute myocardial infarction].

[Neuroprotective treatment of patients with normal tension glaucoma]

[Effect of cytoprotection on the oxidative processes and endothelial function in elderly patients with ischemic heart disease]

[Protective effects of the regulators of energy metabolism and essentiale in case of nitrite intoxication].

[Mildronate in geriatric patients with cardiac failure].

[Therapeutic efficacy of mildronate in pulmonary diseases].

Carnitine depletion in rat pups from mothers given mildronate: a model of carnitine deficiency in late fetal and neonatal life.

[Definition of therapeutic effect of mildronate in patients with chronic heart failure].

Mildronate: an antiischemic drug for neurological indications.

[Cardiotropic characteristics of mildronat].

Endothelium- and nitric oxide-dependent vasorelaxing activities of gamma-butyrobetaine esters: possible link to the antiischemic activities of mildronate.

[Biochemical mechanisms of mildronate action during ischemic stress].

Fatty acid oxidation and related gene expression in heart depleted of carnitine by mildronate treatment in the rat.

Experimental gastric ulcer: gastro- and duodenoprotective effects of sibusol.

[Impaired blood coagulative properties in the early postresuscitation period and their prevention].

[The use of fatty acid beta-oxidation inhibitor mildronate as monotherapy or in combination with atenolol in patients with left ventricular dysfunction after myocardial infarction].

[Antioxidant activity of mildronate and L-carnitine in the treatment of patients with cerebrovascular diseases].